MRNA vaccination as a safe approach for specific protection from type i allergy

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 55-67

  Weiss, Richard ^a   Scheiblhofer, Sandra ^a   Roesler, Elisabeth ^a   Weinberger, Esther ^a   Thalhamer, Josef ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

allergy; DNA vaccine; hygiene hypothesis; immune modulation; mRNA vaccines; prophylaxis; replicon based DNA; self replicating RNA; vaccination

Indexed keywords

DNA VACCINE; MESSENGER RNA; MRNA VACCINE; RNA VACCINE; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNITY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; TH2 CELL; VACCINATION;

ALLERGENS; HUMANS; HYPERSENSITIVITY; RNA, MESSENGER; VACCINES, SYNTHETIC;

EID: 83155183302     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.168     Document Type: Review

References (133)

1. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat. Rev. Immunol. 8(3), 205-217 (2008). (Pubitemid 351323292)
2. Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr. Opin. Immunol. 20(3), 288-294 (2008).
3. Marenholz I, Kerscher T, Bauerfeind A et al. An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J. Allergy Clin. Immunol. 123(4), 911-916 (2009).
4. Senthilselvan A, Rennie D, Chenard L et al. Association of polymorphisms of toll-like receptor 4 with a reduced prevalence of hay fever and atopy. Ann. Allergy Asthma Immunol. 100(5), 463-468 (2008). (Pubitemid 351668783)
5. Floistrup H, Swartz J, Bergstrom A et al. Allergic disease and sensitization in Steiner school children. J. Allergy Clin. Immunol. 117(1), 59-66 (2006). (Pubitemid 43017140)
6. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 112(3), 352-363 (2004). (Pubitemid 38859512)
7. Braun-Fahrländer C, Gassner M, Grize L et al. Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution. Clin. Exp. Allergy 29(1), 28-34 (1999). (Pubitemid 29067649)
8. Braun-Fahrlander C, Riedler J, Herz U et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med. 347(12), 869-877 (2002).
9. Riedler J, Braun-Fahrlander C, Eder W et al. Exposure to farming in early life and development of asthma and allergy: A cross-sectional survey. Lancet 358(9288), 1129-1133 (2001). (Pubitemid 32971845)
10. Riedler J, Eder W, Oberfeld G, Schreuer M. Austrian children living on a farm have less hay fever, asthma and allergic sensitization. Clin. Exp. Allergy 30(2), 194-200 (2000). (Pubitemid 30095663)
11. Von Ehrenstein OS, Von Mutius E, Illi S, Baumann L, Bohm O, von Kries R. Reduced risk of hay fever and asthma among children of farmers. Clin. Exp. Allergy 30(2), 187-193 (2000). (Pubitemid 30095662)
12. Peters M, Kauth M, Scherner O et al. Arabinogalactan isolated from cowshed dust extract protects mice from allergic airway inflammation and sensitization. J. Allergy Clin. Immunol. 126(3), 648-656.e1-4 (2010).
13. Sudre B, Vacheyrou M, Braun-Fahrlander C et al. High levels of grass pollen inside European dairy farms: a role for the allergy-protective effects of environment? Allergy 64(7), 1068-1073 (2009).
14. von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. Nat. Rev. Immunol. 10(12), 861-868 (2010).
15. Ege MJ, Bieli C, Frei R et al. Prenatal farm exposure is related to the expression of receptors of the innate immunity and to atopic sensitization in school-age children. J. Allergy Clin. Immunol. 117(4), 817-823 (2006).
16. Ege MJ, Frei R, Bieli C et al. Not all farming environments protect against the development of asthma and wheeze in children. J. Allergy Clin. Immunol. 119(5), 1140-1147 (2007). (Pubitemid 46667161)
17. Van Strien RT, Engel R, Holst O et al. Microbial exposure of rural school children, as assessed by levels of N-acetyl-muramic acid in mattress dust, and its association with respiratory health. J. Allergy Clin. Immunol. 113(5), 860-867 (2004). (Pubitemid 38608594)
18. Vogel K, Blumer N, Korthals M et al. Animal shed Bacillus licheniformis spores possess allergy-protective as well as inflammatory properties. J. Allergy Clin. Immunol. 122(2), 307-312, 312.e1-8 (2008).
19. Lauener RP, Birchler T, Adamski J et al. Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children. Lancet 360(9331), 465-466 (2002). (Pubitemid 34880149)
20. Pfefferle PI, Sel S, Ege MJ et al. Cord blood allergen-specific IgE is associated with reduced IFN-g production by cord blood cells: the Protection against Allergy-Study in Rural Environments (PASTURE) study. J. Allergy Clin. Immunol. 122(4), 711-716 (2008).
21. Pauli G, Malling HJ. The current state of recombinant allergens for immunotherapy. Curr. Opin. Allergy Clin. Immunol. 10(6), 575-581 (2010).
22. Kulig M, Bergmann R, Niggemann B, Burow G, Wahn U. Prediction of sensitization to inhalant allergens in childhood: evaluating family history, atopic dermatitis and sensitization to food allergens. The MAS Study Group. Multicentre Allergy Study. Clin. Exp. Allergy 28(11), 1397-1403 (1998). (Pubitemid 28559015)
23. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205(12), 2887-2898 (2008).
24. Bullens DM, De Swerdt A, Dilissen E et al. House dust mite-specific T cells in healthy non-atopic children. Clin. Exp. Allergy 35(12), 1535-1541 (2005).
25. Van Overtvelt L, Wambre E, Maillere B et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J. Immunol. 180(7), 4514-4522 (2008).
26. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 66(6), 725-732 (2011).
27. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 127(1), 18-27; quiz 28-29 (2011).
28. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5(9), 1159-1165 (1993). (Pubitemid 23291165)
29. Wolvers DA, Van Der Cammen MJ, Kraal G. Mucosal tolerance is associated with, but independent of, up-regulation Th2 responses. Immunology 92(3), 328-333 (1997). (Pubitemid 27488143)
30. Fujihashi K, Yamamoto M, McGhee JR, Kiyono H. α β T cell receptor-positive intraepithelial lymphocytes with CD4+, CD8- and CD4+, CD8+ phenotypes from orally immunized mice provide Th2-like function for B cell responses. J. Immunol. 151(12), 6681-6691 (1993).
31. Palomares O, Batanero E, Canamero M, Villalba M, Rodriguez R. Prophylactic intranasal treatment with fragments of 1,3-β-glucanase olive pollen allergen prevents airway inflammation in a murine model of type I allergy. Int. Arch. Allergy Immunol. 139(3), 175-180 (2006).
32. Jarnicki AG, Tsuji T, Thomas WR. Inhibition of mucosal and systemic T(h)2- type immune responses by intranasal peptides containing a dominant T cell epitope of the allergen Der p 1. Int. Immunol. 13(10), 1223-1231 (2001). (Pubitemid 32994522)
33. Wiedermann U, Herz U, Baier K et al. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int. Arch. Allergy Immunol. 126(1), 68-77 (2001). (Pubitemid 32973974)
34. Hufnagl K, Winkler B, Focke M et al. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J. Allergy Clin. Immunol. 116(2), 370-376 (2005). (Pubitemid 41096545)
35. + T cells and protection in airway allergy models. Vaccine 23(24), 3181-3186 (2005).
36. Valenta R, Ball T, Focke M et al. Immunotherapy of allergic disease. Adv. Immunol. 82, 105-153 (2004). (Pubitemid 38213117)
37. van Neerven RJ, Knol EF, Ejrnaes A, Wurtzen PA. IgE-mediated allergenpresentation and blocking antibodies: regulation of T-cell activation in allergy. Int. Arch. Allergy Immunol. 141(2), 119-129 (2006). (Pubitemid 44413287)
38. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin. Exp. Allergy 40(3), 385-397 (2010).
39. Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur. J. Immunol. 29(6), 2026-2036 (1999). (Pubitemid 29265559)
40. Van Ree R, Van Leeuwen WA, Dieges PH et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin. Exp. Allergy 27(1), 68-74 (1997). (Pubitemid 27051365)
41. Mark A, Bjorksten B, Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 13(7), 669-673 (1995).
42. Focke M, Linhart B, Hartl A et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin. Exp. Allergy 34(10), 1525-1533 (2004). (Pubitemid 39389328)
43. Kundig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. 117(6), 1470-1476 (2006). (Pubitemid 43795737)
44. Thunberg S, Neimert-Andersson T, Cheng Q et al. Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice. Allergy 64(6), 919-926 (2009).
45. Akoum H, Tsicopoulos A, Vorng H et al. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes. Immunology 87(4), 593-598 (1996). (Pubitemid 26117578)
46. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-g secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154(8), 4187-4194 (1995).
47. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27(9), 1007-1015 (1997).
48. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 92(2), 644-651 (1993). (Pubitemid 23262381)
49. Wachholz PA, Nouri-Aria KT, Wilson DR et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 105(1), 56-62 (2002). (Pubitemid 34128040)
50. Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin. Exp. Allergy 29(10), 1326-1335 (1999). (Pubitemid 29467956)
51. Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J. Immunol. 184(4), 2194-2203 (2010).
52. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J. Allergy Clin. Immunol. 120(3), 707-713 (2007). (Pubitemid 47320765)
53. Wheeler A, Woroniecki S. Immunological adjuvants in allergy vaccines: past, present and future. Allergol. Intl. 50(4), 295-301 (2001). (Pubitemid 33123386)
54. Johansen P, Senti G, Martinez Gomez JM et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy 35(12), 1591-1598 (2005).
55. Martinez Gomez JM, Fischer S, Csaba N et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm. Res. 24(10), 1927-1935 (2007). (Pubitemid 47389249)
56. Marazuela EG, Prado N, Moro E et al. Intranasal vaccination with poly(lactide-co-glycolide) microparticles containing a peptide T of Ole e 1 prevents mice against sensitization. Clin. Exp. Allergy 38(3), 520-528 (2008). (Pubitemid 351208087)
57. Peng HJ, Tsai LC, Su SN et al. Comparison of different adjuvants of protein and DNA vaccination for the prophylaxis of IgE antibody formation. Vaccine 22(5-6), 755-761 (2004).
58. Chisholm D, Libet L, Hayashi T, Horner AA. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J. Allergy Clin. Immunol. 113(3), 448-454 (2004). (Pubitemid 38338949)
59. Duechs MJ, Hahn C, Benediktus E et al. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm. Pharmacol. Ther. 24(2), 203-214 (2011).
60. Jacquet A, Vanderschrick JF, Vandenbranden M et al. Vaccination with the recombinant allergen ProDer p 1 complexed with the cationic lipid DiC14- amidine prevents allergic responses to house dust mite. Mol. Ther. 11(6), 960-968 (2005). (Pubitemid 40724115)
61. Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS. A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology 97(3), 515-521 (1999). (Pubitemid 29314650)
62. Adam E, Delbrassine L, Bouillot C et al. Probiotic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway. Eur. J. Immunol. 40(7), 1995-2005 (2010).
63. Bickert T, Trujillo-Vargas CM, Duechs M et al. Probiotic Escherichia coli Nissle 1917 suppresses allergen-induced Th2 responses in the airways. Int. Arch. Allergy Immunol. 149(3), 219-230 (2009).
64. Daniel C, Repa A, Wild C et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61(7), 812-819 (2006). (Pubitemid 43893983)
65. Rigaux P, Daniel C, Hisbergues M et al. Immunomodulatory properties of Lactobacillus plantarum and its use as a recombinant vaccine against mite allergy. Allergy 64(3), 406-414 (2009).
66. Schwarzer M, Repa A, Daniel C et al. Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization. Allergy 66(3), 368-375 (2011).
67. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr. Gene Ther. 11(3), 189-217 (2011).
68. Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G. Vaccination with a modified vaccinia virus Ankara-based vaccine protects mice from allergic sensitization. J. Gene Med. 10(12), 1324-1333 (2008).
69. Raz E, Tighe H, Sato Y et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl Acad. Sci. USA 93(10), 5141-5145 (1996). (Pubitemid 26162885)
70. Chua KY, Kuo IC, Huang CH. DNA vaccines for the prevention and treatment of allergy. Curr. Opin. Allergy Clin. Immunol. 9(1), 50-54 (2009).
71. Weiss R, Scheiblhofer S, Gabler M, Ferreira F, Leitner WW, Thalhamer J. Is genetic vaccination against allergy possible? Int. Arch. Allergy Immunol. 139(4), 332-345 (2006).
72. Hochreiter R, Stepanoska T, Ferreira F et al. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur. J. Immunol. 33(6), 1667-1676 (2003). (Pubitemid 36790428)
73. Purohit A, Niederberger V, Kronqvist M et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy 38(9), 1514-1525 (2008).
74. Bauer R, Scheiblhofer S, Kern K et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J. Allergy Clin. Immunol. 118(1), 269-276 (2006). (Pubitemid 43946474)
75. Thalhamer T, Dobias H, Stepanoska T et al. Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. J. Allergy Clin. Immunol. 125(4), 926-934.e10 (2010).
76. Bauer R, Himly M, Dedic A, Ferreira F, Thalhamer J, Hartl A. Optimization of codon usage is required for effective genetic immunization against Art v 1, the major allergen of mugwort pollen. Allergy 58(10), 1003-1010 (2003). (Pubitemid 37260342)
77. Jacquet A, Magi M, Haumont M, Jurado M, Garcia L, Bollen A. Absence of immunoglobulin E synthesis and airway eosinophilia by vaccination with plasmid DNA encoding ProDer p 1. Clin. Exp. Allergy 33(2), 218-225 (2003). (Pubitemid 36241380)
78. Massaer M, Mazzu P, Haumont M et al. High-level expression in mammalian cells of recombinant house dust mite allergen ProDer p 1 with optimized codon usage. Int Arch. Allergy Immunol. 125(1), 32-43 (2001). (Pubitemid 32511098)
79. Gabler M, Scheiblhofer S, Kern K et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J. Allergy Clin. Immunol. 118(3), 734-741 (2006). (Pubitemid 44301385)
80. Scheiblhofer S, Gabler M, Leitner WW et al. Inhibition of type I allergic responses with nanogram doses of replicon-based DNA vaccines. Allergy 61(7), 828-835 (2006). (Pubitemid 43898613)
81. Manam S, Ledwith BJ, Barnum AB et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43(4-6), 273-281 (2000). (Pubitemid 32225698)
82. Martin T, Parker SE, Hedstrom R et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum. Gene Ther. 10(5), 759-768 (1999). (Pubitemid 29168160)
83. Probst J, Brechtel S, Scheel B et al. Characterization of the ribonuclease activity on the skin surface. Genet. Vaccines Ther. 4, 4 (2006).
84. Probst J, Weide B, Scheel B et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 14(15), 1175-1180 (2007). (Pubitemid 47086748)
85. Roesler E, Weiss R, Weinberger EE et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J. Allergy Clin. Immunol. 124(5), 1070-1077.e1-11 (2009).
86. Pascolo S. Messenger RNA-based vaccines. Expert. Opin. Biol. Ther. 4(8), 1285-1294 (2004). (Pubitemid 39005734)
87. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol. Lett. 115(1), 33-42 (2008). (Pubitemid 350298588)
88. Tavernier G, Andries O, Demeester J, Sanders NN, De Smedt SC, Rejman J. mRNA as gene therapeutic: how to control protein expression. J. Control Release 150(3), 238-247 (2011).
89. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30(1), 1-7 (2000).
90. Weide B, Carralot JP, Reese A et al. Results of the first Phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31(2), 180-188 (2008).
91. Weide B, Pascolo S, Scheel B et al. Direct injection of protamine-protected mRNA: results of a Phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32(5), 498-507 (2009).
92. Rittig SM, Haentschel M, Weimer KJ et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 19(5), 990-999 (2011).
93. Holtkamp S, Kreiter S, Selmi A et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108(13), 4009-4017 (2006). (Pubitemid 44913269)
94. Kuhn AN, Diken M, Kreiter S et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 17(8), 961-971 (2010).
95. Grillo G, Turi A, Licciulli F et al. UTRdb and UTRsite (RELEASE 2010): a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. Nucleic Acids Res. 38(Database Issue), D75-D80 (2010).
96. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18(9-10), 765-777 (1999).
97. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5(7), 730-737 (2004). (Pubitemid 39023305)
98. Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22(11-12), 1537-1544 (2004). (Pubitemid 38446932)
99. Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP. Type I interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 24(24), 5110-5118 (2006). (Pubitemid 43818199)
100. Scheel B, Braedel S, Probst J et al. Immunostimulating capacities of stabilizedRNA molecules. Eur. J. Immunol. 34(2), 537-547 (2004).
101. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663), 1529-1531 (2004). (Pubitemid 38314425)
102. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004). (Pubitemid 38314424)
103. Diebold SS, Schulz O, Alexopoulou L, Leitner WW, Flavell RA, Reis e Sousa C. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther. 16(3), 359-366 (2009).
104. Budker V, Budker T, Zhang G, Subbotin V, Loomis A, Wolff JA. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J. Gene Med. 2(2), 76-88 (2000).
105. Wolff JA, Dowty ME, Jiao S et al. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J. Cell Sci. 103 (Pt 4), 1249-1259 (1992). (Pubitemid 23042268)
106. Basner-Tschakarjan E, Mirmohammadsadegh A, Baer A, Hengge UR. Uptake and trafficking of DNA in keratinocytes: evidence for DNA-binding proteins. Gene Ther. 11(9), 765-774 (2004). (Pubitemid 38659755)
107. Trombone AP, Silva CL, Lima KM et al. Endocytosis of DNA-Hsp65 alters the pH of the late endosome/lysosome and interferes with antigen presentation. PLoS One 2(9), e923 (2007).
108. Levy MY, Barron LG, Meyer KB, Szoka FC Jr. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther. 3(3), 201-211 (1996). (Pubitemid 26120420)
109. Schubbert R, Renz D, Schmitz B, Doerfler W. Foreign (M13) DNA ingested by mice reaches peripheral leukocytes, spleen, and liver via the intestinal wall mucosa and can be covalently linked to mouse DNA. Proc. Natl Acad. Sci. USA 94(3), 961-966 (1997). (Pubitemid 27074430)
110. Saleh MC, Van Rij RP, Hekele A et al. The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nat. Cell Biol. 8(8), 793-802 (2006). (Pubitemid 44151582)
111. Lehmann MJ, Sczakiel G. Spontaneous uptake of biologically active recombinant DNA by mammalian cells via a selected DNA segment. Gene Ther. 12(5), 446-451 (2005). (Pubitemid 40394297)
112. Wheeler M, Cortez-Gonzalez X, Frazzi R, Zanetti M. Ex vivo programming of antigen-presenting B lymphocytes: considerations on DNA uptake and cell activation. Int. Rev. Immunol. 25(3-4), 83-97 (2006). (Pubitemid 44034575)
113. Lorenz C, Fotin-Mleczek M, Roth G et al. Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. 8(4), 627-636 (2011).
114. Lechardeur D, Lukacs GL. Nucleocytoplasmic transport of plasmid DNA: a perilous journey from the cytoplasm to the nucleus. Hum. Gene Ther. 17(9), 882-889 (2006). (Pubitemid 46076748)
115. Ponsaerts P, Van Tendeloo VF, Berneman ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin. Exp. Immunol. 134(3), 378-384 (2003). (Pubitemid 37542075)
116. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7(23), 2028-2035 (2000). (Pubitemid 32036769)
117. Martinon F, Krishnan S, Lenzen G et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23(7), 1719-1722 (1993). (Pubitemid 23218089)
118. Mockey M, Bourseau E, Chandrashekhar V et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14(9), 802-814 (2007). (Pubitemid 47262757)
119. Fotin-Mleczek M, Duchardt KM, Lorenz C et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011).
120. Kreiter S, Selmi A, Diken M et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70(22), 9031-9040 (2010).
121. Maloy KJ, Erdmann I, Basch V et al. Intralymphatic immunization enhances DNA vaccination. Proc. Natl Acad. Sci. USA 98(6), 3299-3303 (2001). (Pubitemid 32220840)
122. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr. Top. Microbiol. Immunol. 820, 71-84 (2011).
123. Mandl CW, Aberle JH, Aberle SW, Holzmann H, Allison SL, Heinz FX. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat. Med. 4(12), 1438-1440 (1998). (Pubitemid 28553470)
124. Steitz J, Britten CM, Wolfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol. Immunother. 55(3), 246-253 (2006). (Pubitemid 41682573)
125. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40(1), 86-97 (2006). (Pubitemid 44419542)
126. Scheiblhofer S, Stoecklinger A, Gruber C et al. Gene gun immunization with clinically relevant allergens aggravates allergen induced pathology and is contraindicated for allergen immunotherapy. Mol. Immunol. 44(8), 1879-1887 (2007).
127. Weiss R, Scheiblhofer S, Roesler E, Ferreira F, Thalhamer J. Prophylactic mRNA vaccination against allergy. Curr. Opin. Allergy Clin. Immunol. 10(6), 567-574 (2010).
128. Carralot JP, Probst J, Hoerr I et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol. Life Sci. 61(18), 2418-2424 (2004). (Pubitemid 39382031)
129. Kyte JA, Kvalheim G, Lislerud K et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol. Immunother. 56(5), 659-675 (2007). (Pubitemid 46348735)
130. Aberle JH, Aberle SW, Kofler RM, Mandl CW. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J. Virol. 79(24), 15107-15113 (2005). (Pubitemid 43032293)
131. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J. Exp. Med. 174(5), 969-974 (1991).
132. Guo PX, Moss B. Interaction and mutual stabilization of the two subunits of vaccinia virus mRNA capping enzyme coexpressed in Escherichia coli. Proc. Natl Acad. Sci. USA 87(11), 4023-4027 (1990).
133. Pascolo S. RNA-based therapies. In: Drug Discovery Handbook. Gad SC (Ed.). John Wiley & Sons, Hoboken, NJ, USA, 1259-1308 (2005).